Amar Kishan, MD
Enriched profileProfessor with Tenure and Executive Vice Chair, Department of Radiation Oncology, David Geffen School of Medicine at UCLA; Chief, Genitourinary Service · University of California, Los Angeles
Amar Kishan is Professor with Tenure and Executive Vice Chair, Department of Radiation Oncology, David Geffen School of Medicine at UCLA; Chief, Genitourinary Service at University of California, Los Angeles. OpenAlex indexes 314 publications with 7,664 citations (h-index 37); ClinicalTrials.gov lists 12 registered studies with this person as an investigator.
Data verified 25 Aug 2026
Overview
Updated 16 Oct 2026
Amar Kishan, M.D., is Professor with Tenure and Executive Vice Chair, Department of Radiation Oncology, David Geffen School of Medicine at UCLA at University of California, Los Angeles (David Geffen School of Medicine / UCLA Health). The public record shows 314 publications with 7,664 citations (h-index 37), centered on Prostate Cancer Diagnosis and Treatment, Prostate Cancer Treatment and Research, Advanced Radiotherapy Techniques. It also documents an investigator role on 12 registered clinical trials, industry payments reported by 11 companies, 1 NIH-funded awards (2024–2026).
- Most recent indexed publication: 2026 · Journal of clinical oncology
- Top research focus: Prostate Cancer Diagnosis and Treatment
- 12 registered trials on ClinicalTrials.gov
- Open Payments reporting from 11 companies
Generated from the cited public record · current as of 16 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 22 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 126.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 16 Oct 2026
Listed as an investigator on 12 registered studies on ClinicalTrials.gov. The most recent:
- Vascular Optimized Radiotherapy Tuned to Critical Structures for Erectile Function Using High-Precision X-Ray Treatment
Sponsor: Jonsson Comprehensive Cancer Center
- Computed Tomography-Guided Stereotactic Body Radiation Therapy With Intrafraction Motion Monitoring for the Treatment of Localized Prostate Cancer, ILLUSION Trial
Sponsor: Jonsson Comprehensive Cancer Center
Industry payments
Updated 16 Oct 2026
11 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- LANTHEUS MEDICAL IMAGING, INC.Program year20254 payments$14,550openpaymentsdata.cms.gov ↗
- Siemens Medical Solutions USA, Inc.Program year20253 payments
- Janssen Scientific Affairs, LLCProgram year20251 payment
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Genitourinary & hormones
100%alpha-Adrenergic Blocker100%Tamsulosin Hcl100%Part D≥36 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 16 Oct 2026
1 NIH research award on record, funded 2024–2026 per NIH RePORTER. The latest:
- Reducing toxicity from prostate cancer radiotherapy through genetics and technology
University of California Los Angeles
FY2026$360,281R37CA292795 - Reducing toxicity from prostate cancer radiotherapy through genetics and technology
University of California Los Angeles
FY2025$360,281R37CA292795 - Reducing toxicity from prostate cancer radiotherapy through genetics and technology
University of California Los Angeles
FY2024$360,281R37CA292795
Congress activity
Updated 16 Oct 2026
58 congress contributions (2012–2025) across AACR, ASCO, ASTRO, ESMO per OpenAlex. The most recent:
- Individual patient data (IPD) analysis of early PSA nadir in ARASENS, LATITUDE, and TITAN: Training and validation of a novel model.
ASCO Annual Meeting
ASCO2025Co-author - Harnessing Deep Learning on Fractional Dosimetry for Acute Genitourinary Toxicity Prediction Following Prostate SBRT
ASTRO Annual Meeting
ASTRO2025Co-author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 16 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Reply to: Comments on the LUNAR Trial in Oligorecurrent Hormone-Sensitive Prostate Cancer.
Journal of clinical oncology
Article2026 - Local salvage therapies in patients with radio-recurrent prostate cancer following external beam radiotherapy: a systematic review and meta-analysis.
Prostate cancer and prostatic diseases
Meta-analysis2025 - Cross-Comparison Individual Patient-Level Analysis of Three Gene Expression Signatures in Localized Prostate in Over 50,000 Men.
JCO precision oncology
Article2025
Most-cited works
by citation count (OpenAlex)- 01
- 02
- 03Association of Black Race With Prostate Cancer–Specific and Other-Cause MortalityArticle414 citations2019
- 04
- 05
Network
Updated 16 Oct 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 16 Oct 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/amar-kishan-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗ - Other
profiles.ucla.edu/amar.kishan
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →profiles.ucla.edu ↗ - ResearchGate
researchgate.net/profile/Amar-Kishan
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →researchgate.net ↗ - X / Twitter
x.com/AmarUKishan
Mentions by others
where others cite or feature them- Other
oncodaily.com/voices/amar-kishan-483708
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →oncodaily.com ↗ - Other
astro.org/news-and-publications/news-and-media-center/media-resources/astro-experts-for-media/bios/amar-kishan
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →astro.org ↗ - Other
backtable.com/shows/urology/contributors/dr-amar-kishan
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →backtable.com ↗ - Other
guoncologynow.com/author/amar-kishan-md
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →guoncologynow.com ↗ - YouTube
youtube.com/watch
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →youtube.com ↗ - LinkedIn
LinkedIn profile listing title "Professor and Executive Vice Chair" consistent with institutional record (auth-walled, corroborated via SERP snippet only)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →linkedin.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 16 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →uclahealth.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →uclahealth.org ↗
- Board Certified
American Board of Radiology (Radiation Oncology)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →health.usnews.com ↗
Editorial & leadership roles
journal and society appointments- Chair
Prostate/GU Resource Panel, American Society for Radiation Oncology (ASTRO)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →astro.org ↗ - Panel member
NCCN Clinical Practice Guidelines in Oncology, Prostate Cancer
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →jnccn.org ↗ - Member
UCLA Jonsson Comprehensive Cancer Center
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →uclahealth.org ↗
Awards & honors
honors on the public record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →newsroom.ucla.edu ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →newsroom.ucla.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medschool.ucla.edu ↗
Secondary affiliations
appointments beyond the home institution- Co-Director
Cancer Molecular Imaging, Nanotechnology and Theranostics Program, UCLA Jonsson Comprehensive Cancer Center
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →uclahealth.org ↗ - Faculty
Institute for Urologic Oncology, UCLA Health (Department of Urology)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →uclahealth.org ↗
Media & interviews
press, podcasts and appearances- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →labusinessjournal.com ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →thelancetoncology.buzzsprout.com ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →backtable.com ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →onclive.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Dennis Slamon, MD
University of California, Los Angeles
Richard Casaburi, MD
University of California, Los Angeles
Robert Modlin, MD
University of California, Los Angeles
Zev Wainberg, MD
University of California, Los Angeles
Howard Scher, MD
Memorial Sloan Kettering Cancer Center
Toni Choueiri, MD
Dana-Farber Cancer Institute
Robert Motzer, MD
Memorial Sloan Kettering Cancer Center
Fred Saad, MD
Centre hospitalier de l'Université de Montréal (CHUM)